株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

下肢静止不能症候群 : パイプライン分析

Restless Legs Syndrome - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 192807
出版日 ページ情報 英文 44 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.37円で換算しております。
Back to Top
下肢静止不能症候群 : パイプライン分析 Restless Legs Syndrome - Pipeline Review, H2 2017
出版日: 2017年07月11日 ページ情報: 英文 44 Pages
概要

下肢静止不能症候群(RLS、レストレスレッグス症候群)とは、別名ウィリス・エクボム病(WED)とも呼ばれる、神経系の一部の障害です。脚部に作用し、しきりに脚を動かしたくなるようになります。症状には痒みや疼痛、むず痒い感覚、ふくらはぎや脚部の痙攣などが含まれています。主な疾病素質としては、加齢などが想定されています。この疾患の治療薬には、筋弛緩剤や睡眠薬、麻酔薬などがあります。

当レポートでは、世界各国での下肢静止不能症候群(むずむず脚症候群)治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査して、その結果をお届けします。

目次

イントロダクション

  • 分析範囲

下肢静止不能症候群の概要

治療薬の開発

  • 下肢静止不能症候群向けパイプライン製品:概要
  • 下肢静止不能症候群向けパイプライン製品:比較分析

各企業で開発中の下肢静止不能症候群治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

下肢静止不能症候群治療薬:開発中の製品の一覧(企業別)

下肢静止不能症候群治療薬の開発に従事している企業

  • Alexza Pharmaceuticals, Inc.
  • Ascendis Pharma A/S
  • 久光製薬
  • Ligand Pharmaceuticals, Inc.
  • Mundipharma International Ltd
  • Omeros Corporation
  • Serina Therapeutics, Inc.
  • Vifor Pharma AG

下肢静止不能症候群:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 機能メカニズム別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • (塩酸ナロキソン+塩酸オキシコドン)ER
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • フマル酸アプリンドル
  • AZ-008
  • カルボキシマルトース鉄(鉄欠乏性貧血治療)
  • OMS-527
  • 二塩酸塩プラミペキソール
  • 塩酸ロピニロール
  • SER-214

下肢静止不能症候群治療薬:最新の薬剤プロファイル

下肢静止不能症候群治療薬:開発が休止状態の製品

下肢静止不能症候群治療薬:開発が中止された製品

下肢静止不能症候群関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9506IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Restless Legs Syndrome - Pipeline Review, H2 2017, provides an overview of the Restless Legs Syndrome (Central Nervous System) pipeline landscape.

Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a disorder of the part of the nervous system that affects the legs and causes an urge to move them. Symptoms include itching, pain, a creepy-crawly feeling and cramping in the calf's or legs. Predisposing factor includes age. Treatment includes muscle relaxants, sleep medications and narcotic medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Restless Legs Syndrome - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Restless Legs Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Restless Legs Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Restless Legs Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 3, 1 and 2 respectively.

Restless Legs Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Restless Legs Syndrome (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Restless Legs Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Restless Legs Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Restless Legs Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Restless Legs Syndrome (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Restless Legs Syndrome (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Restless Legs Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Restless Legs Syndrome - Overview
    • Restless Legs Syndrome - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Restless Legs Syndrome - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Restless Legs Syndrome - Companies Involved in Therapeutics Development
    • Galenica Ltd
    • Hisamitsu Pharmaceutical Co Inc
    • Merz Pharma GmbH & Co KgaA
    • Mundipharma International Ltd
    • Omeros Corp
    • Serina Therapeutics Inc
  • Restless Legs Syndrome - Drug Profiles
    • (cannabidiol + dronabinol) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (naloxone hydrochloride + oxycodone hydrochloride) ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aplindore fumarate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ferric carboxymaltose - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • incobotulinumtoxin A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMS-527 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ropinirole hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SER-214 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Restless Legs Syndrome - Dormant Projects
  • Restless Legs Syndrome - Discontinued Products
  • Restless Legs Syndrome - Product Development Milestones
    • Featured News & Press Releases
      • May 29, 2015: Napp receives approval from MHRA to prescribe Targinact (oxycodone/naloxone) for the treatment of Restless Legs
      • Jan 07, 2015: Mundipharma receives positive European Commission decision on Targin (oxycodone/naloxone) for the treatment of Restless Legs Syndrome
      • Oct 24, 2014: Mundipharma receives Positive CHMP Opinion for Targin (oxycodone / naloxone) for the treatment of Restless Legs Syndrome
      • Oct 23, 2014: Hisamitsu Announces the results of Phase II clinical study of HP-3000 in Japan (a transdermal system for the treatment of idiopathic restless legs syndrome)
      • Nov 19, 2013: New data show efficacy of prolonged release TARGIN (oxycodone / naloxone) in the treatment of severe restless legs syndrome
      • Oct 16, 2008: Neurogen Announces Positive Top-Line Results From Two Phase II Trials For Aplindore In Restless Legs Syndrome And Parkinson's Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Restless Legs Syndrome, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Restless Legs Syndrome - Pipeline by Galenica Ltd, H2 2017
  • Restless Legs Syndrome - Pipeline by Hisamitsu Pharmaceutical Co Inc, H2 2017
  • Restless Legs Syndrome - Pipeline by Merz Pharma GmbH & Co KgaA, H2 2017
  • Restless Legs Syndrome - Pipeline by Mundipharma International Ltd, H2 2017
  • Restless Legs Syndrome - Pipeline by Omeros Corp, H2 2017
  • Restless Legs Syndrome - Pipeline by Serina Therapeutics Inc, H2 2017
  • Restless Legs Syndrome - Dormant Projects, H2 2017
  • Restless Legs Syndrome - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Restless Legs Syndrome, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top